Ishmael Jaiyesimi, DO
Hematology & Oncology · Royal Oak, MINPI 1538128178
Payments from drug & device makers
Across 212 payments — averaging $2449.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$390K
- Merck$102K
- AstraZeneca$16K
- QED Therapeutics, Inc.$4K
- Novartis$3K
- Johnson & Johnson$2K
- plus $3K from 34 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 9 | $390,232 |
| Merck | 6 | $101,509 |
| AstraZeneca | 5 | $15,673 |
| QED Therapeutics, Inc. | 2 | $3,810 |
| Novartis | 60 | $2,844 |
| Johnson & Johnson(2 entities) | 11 | $2,110 |
| Gilead(2 entities) | 10 | $410 |
| Pfizer | 13 | $206 |
| Genentech USA, Inc. | 10 | $196 |
| Bristol Myers Squibb | 9 | $195 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $183 |
| Daiichi Sankyo Inc. | 4 | $180 |
| Astellas Pharma US Inc | 8 | $161 |
| Coherus Oncology, Inc. | 4 | $158 |
| Janssen Scientific Affairs, LLC | 1 | $148 |
| Sanofi | 6 | $141 |
| Foundation Medicine, Inc. | 1 | $131 |
| GSK | 6 | $120 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Array Biopharma Inc | 6 | $101 |
| Incyte Corporation | 1 | $65 |
| AbbVie | 2 | $59 |
| EMD Serono, Inc. | 2 | $54 |
| Taiho Oncology, Inc. | 2 | $51 |
| Morphosys, US Inc. | 3 | $50 |
| Genmab U.S., Inc. | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Seagen Inc. | 2 | $39 |
| Pharmaessentia USA Corporation | 2 | $36 |
| Tersera Therapeutics LLC | 2 | $35 |
| Rigel Pharmaceuticals, Inc. | 2 | $34 |
| Tesaro, Inc. | 1 | $28 |
| Bayer | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Exelixis Inc. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $21 |
| Tempus AI, Inc | 1 | $17 |
| AVEO Pharmaceuticals, Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$519,311 in reported general payments places this provider in the 85th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Royal Oak
- Elisa QuirozRoyal Oak$130K
- Laura NadeauRoyal Oak$54K
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Hirva MamdaniDetroit$9.5M
- Jeffrey ZonderDetroit$8.2M
- Assuntina SaccoAnn Arbor$8.1M
- Abhinav DeolDetroit$4.5M
- Harsh ShahDetroit$2.6M
- Igor RybkinDetroit$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.